Autres langues Nektar Therapeutics

Actions

NKTR

US6402681083

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 24/04/2024			Varia. 5j.	Varia. 1 janv.
1,38 ^USD	-2,13 %		+2,22 %	+144,25 %

24/04	Biolojic Design annonce que Nektar Therapeutics a exercé son option de licence pour développer un anticorps agoniste conçu par l'IA ciblant le TNFR2 pour le traitement des maladies auto-immunes.	CI
05/03	Nektar Therapeutics démarre un essai de phase 2b pour la rezpegaldesleukin chez des patients atteints d'alopécie areata sévère	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Biolojic Design Announces Nektar Therapeutics Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases	24/04
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune and Inflammatory Disease Virtual Conference	25/03
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	22/03
Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC	19/03
Nektar Therapeutics Begins Phase 2b Trial for Rezpegaldesleukin in Patients With Severe Alopecia Areata	05/03
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	05/03
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata	05/03
Nektar: Q4 Earnings Snapshot	04/03
Nektar Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	04/03
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q4 Revenue $23.9M, vs. Street Est of $21.4M	04/03
Nektar Therapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04/03
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX	04/03
North American Morning Briefing : Stock Futures -2-	04/03
Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC	04/03
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference	28/02
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets	27/02
DiaMedica Therapeutics Names Lorianne Masuoka as Chief Medical Officer	22/01
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA	04/01
Nektar Therapeutics(NasdaqCM:NKTR) dropped from NASDAQ Biotechnology Index	15/12
Nektar Therapeutics Reports Positive Preclinical Data on NKTR-255	12/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Nektar Therapeutics

Actions

NKTR

US6402681083

Autres langues

Filtres